The analysis was retrospective and limited to a subset of RESPECT trial participants, and the sample size, although among the largest datasets with genomic profiling in older patients with HER2+ breast cancer, remains modest, particularly for subgroup and interaction analyses. This evidence concerns the gene ERBB2 and breast carcinoma.